Srini Akkaraju Akkaraju
Presidente en JIYA ACQUISITION CORP. .
Fortuna: 13 597 $ al 30/04/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Richard D. van Doren | M | 47 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
Theia Therapeutics, Inc.
Autobahn Labs, Inc.
Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | 8 años |
Perry Karsen | M | 69 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
Autobahn Labs, Inc.
Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | 4 años |
Eric Dobmeier | M | 55 |
Chinook Therapeutics U.S., Inc.
Chinook Therapeutics U.S., Inc. Information Technology ServicesTechnology Services Chinook Therapeutics U.S., Inc. operates as a development stage company. The company is headquartered in Seattle, WA. | 4 años |
Timothy Kutzkey | M | 49 |
Stanford University
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | 5 años |
Cory Freedland | M | 48 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
Tentarix Biotherapeutics, Inc.
| 7 años |
Sanjay Shukla | M | 52 | 8 años | |
Michael Dybbs | M | 49 |
Samsara BioCapital LP
Samsara BioCapital LP Investment ManagersFinance Samsara Biocapital LP invests in companies located in the US. The fund targets companies operating in the fields of biotechnology and pharmaceuticals. It provides financing for early stage capital requirements.
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
565 SPV I LP
565 SPV I LP Investment ManagersFinance 565 SPV I LP provides investment services. The company is headquartered in Palo Alto, CA.
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group. | 15 años |
Glenn Sblendorio | M | 68 | 10 años | |
Amir Nashat | M | 51 |
Dewpoint Therapeutics, Inc.
Dewpoint Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dewpoint Therapeutics, Inc. develops drugs. The company is headquartered in Boston, MA. | 10 años |
David Guyer | M | 64 |
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | 3 años |
Jerel Davis | M | 47 |
Tentarix Biotherapeutics, Inc.
| 6 años |
Rajiv Doshi | M | - |
Piper Biosciences, Inc.
Piper Biosciences, Inc. Pharmaceuticals: OtherHealth Technology Piper Biosciences, Inc. manufactures and sells cholesterol-lowering gummies with plant sterols. It offers cholesterol wellness kits.The company was founded by Rajiv Doshi and is headquartered in Los Altos, CA. | - |
Dolca Thomas | M | 53 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 4 años |
Conley Chee | M | 54 | 3 años | |
Jay Backstrom | M | 69 | 2 años | |
Tim Tyson | M | 71 | 2 años | |
Sushma Gambhir | F | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 4 años |
Mani Subramanian | M | - |
OrsoBio Inc
OrsoBio Inc Miscellaneous Commercial ServicesCommercial Services Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation.
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 4 años |
Roger Zhang | M | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 4 años |
Adam Levy | M | 46 | 2 años | |
Katie Peng | F | - | - | |
Richard Brudnick | M | 67 | 1 años | |
Derek DiRocco | M | 43 | 2 años | |
Andrew Oh | M | 53 | 2 años | |
Eliot Charles | M | 62 |
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group.
MiroBio Ltd.
MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | 7 años |
Karen Hunady | F | - | 2 años | |
Noopur Liffick | F | - | 4 años | |
Stephen MacMahon | M | - |
The George Institute for Global Health
The George Institute for Global Health Miscellaneous Commercial ServicesCommercial Services The George Institute for Global Health provides research and development for international health. It develops tools to empower people to improve their own health. The firm also uses mobile technology to make healthcare accessible worldwide and improves outcomes among stroke survivors. It helps preventing complications of diabetes. The company was founded by Stephen MacMahon and Robyn Norton in 1999 and is headquartered in Sydney, Australia. | 25 años |
Dan Spiegelman | M | 65 | 4 años | |
Daphne Karydas | F | 49 | 1 años | |
Stephen Shuttleworth | M | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
Autobahn Labs, Inc.
Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | 5 años |
Nils Lonberg | M | 68 |
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | - |
Tim Coughlin | M | 57 | 7 años | |
Robert Stein | M | 73 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.
Autobahn Labs, Inc.
Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | 6 años |
Alexander G. Asam | M | 58 | 3 años | |
S. Gail Eckhardt | M | 66 | 4 años | |
Olivier Litzka | M | 56 | 2 años | |
Murari Srinivasan | M | - |
Codex Health, Inc.
Codex Health, Inc. Packaged SoftwareTechnology Services Codex Health, Inc. is a company based in Palo Alto, CA. Codex Health specializes in disease management with AI-powered clinical intelligence. The company's products enable healthcare organizations to deliver better outcomes, reduce costs, and improve the overall patient experience. Codex Health, Inc. offers a modern approach to chronic disease management, providing personalized care that is seamlessly linked to the patient's care team. Codex Health also offers next-generation population health management, equipping patients with personalized experiences and supporting them in their self-care journey. The company provides targeted proactive care, identifying at-risk patients and managing them proactively to mitigate adverse events. Codex Health's solutions enable scalable continuous and asynchronous care, extending clinical care into the patient's daily life. The company also helps healthcare systems maximize revenue by optimizing patients' outcomes based on deep clinical and operational visibility into risk and outcomes. The company was founded by Murari Srinivasan and Srinivas Akkaraju, with Murari Srinivasan serving as the CEO since incorporation. | - |
Deborah Dunsire | M | 61 | 3 años | |
Steve Kelsey | M | 63 | 4 años | |
Meysis Lam | F | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 3 años |
Levi Smith | M | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 3 años |
Aditya Asokan | M | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 4 años |
Yogen K. Dalal | M | - |
Piper Biosciences, Inc.
Piper Biosciences, Inc. Pharmaceuticals: OtherHealth Technology Piper Biosciences, Inc. manufactures and sells cholesterol-lowering gummies with plant sterols. It offers cholesterol wellness kits.The company was founded by Rajiv Doshi and is headquartered in Los Altos, CA. | - |
Sarah Milsom | F | - |
Eyebiotech Ltd.
Eyebiotech Ltd. Pharmaceuticals: MajorHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | 3 años |
Jason Haas | M | 56 | 3 años | |
Jing Marantz | M | 59 | 2 años | |
Donald Santel | M | 62 |
Tentarix Biotherapeutics LP
Tentarix Biotherapeutics LP BiotechnologyHealth Technology Tentarix Biotherapeutics LP operates as a biotechnology company. The company is headquartered in La Jolla, CA. | 2 años |
Raymond Cheong | M | 42 | - | |
Ravichandran Rao | M | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 2 años |
Robert Baffi | M | 68 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 3 años |
Tracey Sacco | F | 47 | 1 años | |
Chris Richard | M | 54 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 4 años |
Marcos Milla | M | 61 |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 3 años |
Betsy Santos | F | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 2 años |
Brady Johnson | M | - |
Tentarix Biotherapeutics LP
Tentarix Biotherapeutics LP BiotechnologyHealth Technology Tentarix Biotherapeutics LP operates as a biotechnology company. The company is headquartered in La Jolla, CA. | 2 años |
Napoleone Ferrara | M | 67 |
Theia Therapeutics, Inc.
| - |
Miran Ahmad | M | - |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | 2 años |
Minji Kim | M | - | - | |
Jessica Ibbitson | F | - | 3 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Sanj Patel | M | 54 | 4 años | |
Al Altomari | M | 65 |
Barrier Therapeutics, Inc.
Barrier Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Barrier Therapeutics, Inc. discovers, develops, and commercializes pharmaceutical products in the field of dermatology in the United States. It markets Xolegel, Vusion, and Solage gels. The firm markets its products to dermatologists and other target physicians through sales force. The company was founded in 2001 and is headquartered in Princeton, NJ | 8 años |
Gerald Quirk | M | 56 | 6 años | |
Nagesh Mahanthappa | M | 59 | 1 años | |
Steven M. Leventer | M | 68 | 2 años | |
Geert Cauwenbergh | M | 70 |
Barrier Therapeutics, Inc.
Barrier Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Barrier Therapeutics, Inc. discovers, develops, and commercializes pharmaceutical products in the field of dermatology in the United States. It markets Xolegel, Vusion, and Solage gels. The firm markets its products to dermatologists and other target physicians through sales force. The company was founded in 2001 and is headquartered in Princeton, NJ | 7 años |
Adam Nash | M | - |
Stanford University
| 5 años |
Rekha Hemrajani | F | 54 | 2 años | |
Chih-Kong Ken Yang | M | - |
Stanford University
| 5 años |
Mauria Finley | F | 50 |
Stanford University
| 5 años |
Lawrence S. Malkin | M | - |
Stanford University
| 4 años |
Lori Friedman | M | 60 | - | |
Asha Nayak | M | - |
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group. | - |
Stephen van Horne | M | - |
Stanford University
| 2 años |
Puneet Agarwal | M | - |
Stanford University
| 5 años |
Takeshi Takahashi | M | 48 | 3 años | |
Sean Cao | M | - |
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group. | 1 años |
Sameer Dholakia | M | 50 |
Stanford University
| 4 años |
Girish Putcha | M | - |
Panorama Capital LLC
Panorama Capital LLC Investment ManagersFinance Panorama Capital LLC (Panorama Capita) is a venture capital firm founded in 1995 by Chris Albinson, Rod Ferguson, Shahan Soghikian and damion wicker. The firm is headquartered in Campbell, California.
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | - |
Timur Yarnall | M | - |
Stanford University
| 5 años |
Sasa Zorovic | M | - |
Stanford University
| 6 años |
Mark Heinrich | M | - |
Stanford University
| 5 años |
Jessica Baron | F | 48 |
Stanford University
| 4 años |
Alex Scherbakovsky | M | - |
Stanford University
| 4 años |
Mark Alles | M | 64 | 4 años | |
Hans-Peter Guler | M | 75 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 6 años |
Peter G. Schultz | M | 67 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | - |
Jason Terrance Holzer | M | 52 |
Stanford University
| 4 años |
Kevin Efrusy | M | 51 |
Stanford University
| 5 años |
Kenneth Lin | M | 51 |
Stanford University
Panorama Capital LLC
Panorama Capital LLC Investment ManagersFinance Panorama Capital LLC (Panorama Capita) is a venture capital firm founded in 1995 by Chris Albinson, Rod Ferguson, Shahan Soghikian and damion wicker. The firm is headquartered in Campbell, California. | 4 años |
Laura Shawver | M | 66 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 8 años |
Albert C. Bristow | M | 54 |
Barrier Therapeutics, Inc.
Barrier Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Barrier Therapeutics, Inc. discovers, develops, and commercializes pharmaceutical products in the field of dermatology in the United States. It markets Xolegel, Vusion, and Solage gels. The firm markets its products to dermatologists and other target physicians through sales force. The company was founded in 2001 and is headquartered in Princeton, NJ | 8 años |
Thomas D. Willis | M | - |
Stanford University
| 3 años |
Michael O'Connor | M | - |
Stanford University
| 5 años |
Kevin Stein | M | 58 |
Stanford University
| 5 años |
Anand Rajaraman | M | - |
Stanford University
| 3 años |
Vincent K. Jones | M | - |
Stanford University
| 5 años |
Christopher C. Goodnow | M | - |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 8 años |
Douglas Fisher | M | 48 |
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group. | 3 años |
Tim Roughgarden | M | - |
Stanford University
| 5 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 97 | 97.00% |
Reino Unido | 3 | 3.00% |
Australia | 1 | 1.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Srini Akkaraju Akkaraju
- Red Personal